Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent - PubMed (original) (raw)
Clinical Trial
. 2005 Dec;32(12):1384-91.
doi: 10.1007/s00259-005-1880-2. Epub 2005 Aug 26.
Affiliations
- PMID: 16133382
- DOI: 10.1007/s00259-005-1880-2
Clinical Trial
Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent
Rodney J Hicks et al. Eur J Nucl Med Mol Imaging. 2005 Dec.
Abstract
Purpose: The purpose of the study was to evaluate [(18)F]fluoromisonidazole (FMISO) PET in advanced head and neck cancer during hypoxia-targeting therapy.
Methods: Fifteen of 16 patients in a phase I trial of chemoradiation plus tirapazamine (specific cytotoxin for hypoxic cells) in advanced (T3/4 and/or N2/3) head and neck cancer underwent serial [(18)F]fluorodeoxyglucose (FDG) and FMISO PET. We have previously reported excellent early clinical outcome of these patients and now review FMISO PET results in the context of longer follow-up of this patient cohort.
Results: Based on blinded qualitative scoring by two readers, FMISO PET was positive in 13/15 patients at baseline: 12/15 of primary sites and 8/13 neck nodes were scored as positive. All sites of corresponding FDG and FMISO abnormality at baseline showed marked qualitative reduction of uptake within 4 weeks of commencing therapy, consistent with effective hypoxia-targeted therapy. With a median follow-up of 6.9 years, there have been only four locoregional failures, while three other patients have died of metachronous lung cancer. The 5-year overall survival was 50% (95% CI 27-73%), the 5-year failure-free survival was 44% (95% CI 22-68%) and the 5-year freedom from locoregional failure was 68% (95% CI 38-88%).
Conclusion: The high prevalence of hypoxia demonstrated on FMISO PET imaging is consistent with the advanced disease stage of these patients and would be expected to predict an adverse prognosis. Evidence of the early resolution of FMISO abnormality during treatment, associated with excellent locoregional control in this patient cohort, supports further investigation of hypoxia-targeting agents in advanced head and neck cancer.
Similar articles
- Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer.
Rischin D, Peters L, Hicks R, Hughes P, Fisher R, Hart R, Sexton M, D'Costa I, von Roemeling R. Rischin D, et al. J Clin Oncol. 2001 Jan 15;19(2):535-42. doi: 10.1200/JCO.2001.19.2.535. J Clin Oncol. 2001. PMID: 11208848 Clinical Trial. - Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
Löck S, Perrin R, Seidlitz A, Bandurska-Luque A, Zschaeck S, Zöphel K, Krause M, Steinbach J, Kotzerke J, Zips D, Troost EGC, Baumann M. Löck S, et al. Radiother Oncol. 2017 Sep;124(3):533-540. doi: 10.1016/j.radonc.2017.08.010. Epub 2017 Aug 23. Radiother Oncol. 2017. PMID: 28843726 - PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus.
Kostakoglu L, Goldsmith SJ. Kostakoglu L, et al. J Nucl Med. 2004 Jan;45(1):56-68. J Nucl Med. 2004. PMID: 14734674 Review. - Hypoxia in head and neck cancer: studies with hypoxic positron emission tomography imaging and hypoxic cytotoxins.
Rischin D, Fisher R, Peters L, Corry J, Hicks R. Rischin D, et al. Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S61-3. doi: 10.1016/j.ijrobp.2007.05.043. Int J Radiat Oncol Biol Phys. 2007. PMID: 17848298 Review. No abstract available.
Cited by
- Computerized PET/CT image analysis in the evaluation of tumour response to therapy.
Lu W, Wang J, Zhang HH. Lu W, et al. Br J Radiol. 2015 Apr;88(1048):20140625. doi: 10.1259/bjr.20140625. Epub 2015 Feb 27. Br J Radiol. 2015. PMID: 25723599 Free PMC article. Review. - Bibliometric analysis of the top 100 cited articles in head and neck radiology.
Oo AM, ChuT TS. Oo AM, et al. Acta Radiol Open. 2021 Mar 12;10(3):20584601211001815. doi: 10.1177/20584601211001815. eCollection 2021 Mar. Acta Radiol Open. 2021. PMID: 33786203 Free PMC article. - Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer.
Yoon J, Kang SY, Lee KH, Cheon GJ, Oh DY. Yoon J, et al. Cancer Res Treat. 2021 Apr;53(2):471-479. doi: 10.4143/crt.2020.577. Epub 2020 Oct 22. Cancer Res Treat. 2021. PMID: 33091966 Free PMC article. - Clinical biomarkers of angiogenesis inhibition.
Brown AP, Citrin DE, Camphausen KA. Brown AP, et al. Cancer Metastasis Rev. 2008 Sep;27(3):415-34. doi: 10.1007/s10555-008-9143-x. Cancer Metastasis Rev. 2008. PMID: 18414993 Free PMC article. Review. - Advances in PET and MRI imaging of tumor hypoxia.
Gouel P, Decazes P, Vera P, Gardin I, Thureau S, Bohn P. Gouel P, et al. Front Med (Lausanne). 2023 Feb 9;10:1055062. doi: 10.3389/fmed.2023.1055062. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36844199 Free PMC article. Review.
References
- Radiother Oncol. 1996 Oct;41(1):31-9 - PubMed
- J Clin Oncol. 2001 Jan 15;19(2):535-42 - PubMed
- Lancet. 2000 Mar 18;355(9208):949-55 - PubMed
- Int J Radiat Oncol Biol Phys. 1988 May;14(5):831-8 - PubMed
- Radiother Oncol. 2000 Oct;57(1):39-43 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical